EXEL News and Press, Exelixis Inc. From 02/14/22

Exelixis stock remains stagnant despite strong revenue. Cabo is in a second growth phase here, that's what is keeping the stock stagnant. If it can get out and expand, I see strong potential. For further details see: Exelixis: Rangebound Forever

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its fourth quarter and full year 2021 financial results will be released on Thursday, February 17, 2022 after the markets close. At 5...

- Presentation to be webcast on www.exelixis.com - Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the virtual Guggenheim Healthcare Talks Oncology Day on Wednesday, February 9, 2022 at 1:30pm ET / 10:30am PT. ...

Investing in the stock market won't make you rich overnight. But with a patient approach to investing, coupled with several promising picks that could perform well in the long run, you can become much wealthier by investing in stocks over time. Let's address the second part of this stra...

– Cabozantinib in combination with atezolizumab evaluated in cohort 16 of the phase 1b COSMIC-021 trial demonstrated encouraging clinical activity with a manageable safety profile in patients with previously treated metastatic colorectal cancer – – Cabozan...

— Corporate priorities for 2022 include initial readout of up to three cabozantinib pivotal trials; initiation of pivotal trial program for XL092; expansion of clinical programs for XL092, XB002 and XL102; and multiple new development candidates from small molecule and biolog...

— Exelixis gains full rights to anti-tissue factor antibody used in XB002 plus oncology-specific rights to additional antibodies discovered by Iconic — Exelixis, Inc. (Nasdaq: EXEL) and Iconic Therapeutics, Inc. (Iconic) today announced that the companies have ...

– CONTACT-03 is one of three pivotal trials that are part of an ongoing clinical collaboration with Roche – Exelixis, Inc. (Nasdaq: EXEL) today announced that enrollment is complete for CONTACT-03, the global, phase 3 pivotal trial evaluating the efficacy a...

- Presentation to be webcast on www.exelixis.com - Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the virtual 40 th Annual J.P. M...

– Veteran drug developer’s career spans patient care, the FDA and biopharma – – Dr. Goodman will lead Exelixis’ expansion to the East Coast – Exelixis, Inc. (Nasdaq: EXEL) today announced the appointment of Vicki ...